Effects of ranolazine on wild-type and mutant hNav1.7 channels and on DRG neuron excitability.
BACKGROUND
A direct role of sodium channels in pain has recently been confirmed by establishing a monogenic link between SCN9A, the gene which encodes sodium channel Nav1.7, and pain disorders in humans, with gain-of-function mutations causing severe pain syndromes, and loss-of-function mutations causing congenital indifference to pain. Expression of sodium channel Nav1.8 in DRG neurons has also been shown to be essential for the manifestation of mutant Nav1.7-induced neuronal hyperexcitability. These findings have confirmed key roles of Nav1.7 and Nav1.8 in pain and identify these channels as novel targets for pain therapeutic development. Ranolazine preferentially blocks cardiac late sodium currents at concentrations that do not significantly reduce peak sodium current. Ranolazine also blocks wild-type Nav1.7 and Nav1.8 channels in a use-dependent manner. However, ranolazine's effects on gain-of-function mutations of Nav1.7 and on DRG neuron excitability have not been investigated. We used voltage- and current-clamp recordings to evaluate the hypothesis that ranolazine may be effective in regulating Nav1.7-induced DRG neuron hyperexcitability.


RESULTS
We show that ranolazine produces comparable block of peak and ramp currents of wild-type Nav1.7 and mutant Nav1.7 channels linked to Inherited Erythromelalgia and Paroxysmal Extreme Pain Disorder. We also show that ranolazine, at a clinically-relevant concentration, blocks high-frequency firing of DRG neurons expressing wild-type but not mutant channels.


CONCLUSIONS
Our data suggest that ranalozine can attenuate hyperexcitability of DRG neurons over-expressing wild-type Nav1.7 channels, as occurs in acquired neuropathic and inflammatory pain, and thus merits further study as an alternative to existing non-selective sodium channel blockers.
Department of Neurology, Yale University School of Medicine, New Haven, CT 06510, USA.
Mark
M
Estacion
Stephen G
SG
Waxman
Sulayman D
SD
Dib-Hajj
D000083:Acetanilides / Q000494:pharmacology* / Q000627:therapeutic use; D000787:Angina Pectoris / Q000188:drug therapy; D002460:Cell Line; D005727:Ganglia, Spinal / Q000187:drug effects* / Q000502:physiology; D006801:Humans; D009154:Mutation; D062556:NAV1.7 Voltage-Gated Sodium Channel; D010879:Piperazines / Q000494:pharmacology* / Q000627:therapeutic use; D000069458:Ranolazine; D026941:Sodium Channel Blockers / Q000494:pharmacology* / Q000627:therapeutic use; D015222:Sodium Channels / Q000235:genetics* / Q000378:metabolism*
D000083:Acetanilides; D062556:NAV1.7 Voltage-Gated Sodium Channel; D010879:Piperazines; C486866:SCN9A protein, human; D026941:Sodium Channel Blockers; D015222:Sodium Channels; D000069458:Ranolazine